Telmisartan and Amlodipine Versus Monocomponent Tablets

Summary

This study will be an open-label, randomized, two-treatment, two-period, two-sequence crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer Ingelheim Pharma GmbH \& Co. KGs 80 mg telmisartan/10 mg amlodipine fixed dose combination tablet to the corresponding mono-component amlodipine tablets, 10 mg (Pfizers Norvasc).

Timeline

Start

2011-01

Primary completion

2011-02

Completion

—

Drugs

Indications